It was made during this call, which are not strictly historical, are forward-looking statements within the meaning of the safe harbor provisions of the Federal Securities Law. Top-line sales growth of ...

Bristol-Myers Squibb Co (BMY) reports robust growth in its new product portfolio while navigating revenue declines in its legacy offerings.